Skip to content
Back to Blog
Bio
2026-11-026 min read17

Korea's Bio-Health Exports Hit a Record in October, With Latin America Joining the US and EU — What SMEs in Pharma, Biologics and Medical Devices Need to Prepare for Brazil (ANVISA) and Mexico (COFEPRIS) Market Entry

Korea's bio-health exports reached a record USD 1.53 billion in October, up 30.2% year on year, with Latin America cited as a key driver. This guide covers what pharma, biologics and medical device SMEs need to prepare for ANVISA and COFEPRIS approvals and for export contracts in Brazil and Mexico.

KITIM Consulting Team

October Bio-Health Exports in Numbers

According to the October trade figures released by the Ministry of Trade, Industry and Resources on November 1, Korea's bio-health exports reached USD 1.53 billion in October. That is 30.2% higher than the same month a year earlier and the highest October total on record. The government pointed to two drivers:

  • Market diversification: exports grew beyond the US and EU into Latin America
  • More contract manufacturing (CMO): multi-year agreements raised shipment volumes
  • It helps to separate two stories in these numbers. Multi-year CMO contracts mostly benefit a few companies with large-scale capacity. The expansion into Latin America is different: it is a route that SMEs making finished drugs, biosimilars and medical devices can also use.

    Why Latin America — Market Structure and Entry Routes

    Public procurement led by Brazil and Mexico

    Brazil and Mexico are the region's largest markets. In both countries, public health systems buy a large share of products. As a result, tender pricing and reliable supply matter as much as the product itself.

    Fast-track review based on reference-country approvals

    Brazil's ANVISA and Mexico's COFEPRIS have both introduced or expanded reliance pathways that consider approvals from trusted regulators such as the US FDA and the EMA. Whether a product already has US or EU approval can strongly affect how quickly it reaches the market. However, eligible products, recognized reference authorities and filing requirements change often. Always check the latest regulations immediately before filing.

    A local registration holder is the first hurdle

    In both countries, applications are filed in the name of a local entity or registration holder. A foreign manufacturer will find it hard to hold the approval directly. That makes choosing a partner the first real regulatory decision.

    Key Preparation for ANVISA and COFEPRIS

  • Manufacturing-site GMP: Both regulators assess GMP compliance and may require on-site inspections. Check product by product whether Korean GMP certification or inspection results from PIC/S members can replace or simplify an inspection
  • Local-language dossiers: Submissions are in Portuguese for Brazil and Spanish for Mexico. The quality of translated labels, package inserts and core technical documents directly affects how many deficiency letters you receive
  • Stability data for the right climate zone: Brazil is generally understood to require long-term stability data under hot and humid conditions (30°C/75% RH). If your studies only cover Korean conditions, plan time for additional testing. For Mexico, check the requirements of its national standard (NOM) separately
  • Medical device classification: Brazil uses Classes I–IV and Mexico uses Classes I–III. Procedures and review times vary widely by class, and some electrical devices may need separate certification. Also check whether reference-country certifications can be used
  • Product prioritization: Given approval timelines and costs, it usually makes sense to start with products that already have reference-country approvals and need little additional stability data
  • Export Contracts and Supply Risk

  • Who holds the approval: If the approval is registered to your distributor, it may be hard to transfer when the contract ends. The contract should spell out the registration holder, the scope and term of exclusivity, and an obligation to cooperate in transferring the approval on termination
  • Tender terms vs. production capacity: Public tenders often combine low prices, strict delivery schedules and late-delivery penalties. Confirm in advance that your Korean production capacity can meet awarded volumes
  • Currency and payment risk: To manage volatility in the real and the peso and long payment terms, consider secure payment terms such as letters of credit. We also recommend using export insurance from the Korea Trade Insurance Corporation
  • Government Support and a Step-by-Step Plan

    Available support includes KHIDI's (Korea Health Industry Development Institute) bio-health global expansion programs, help with overseas certification and export costs through programs such as the Export Voucher, and support for overseas regulatory consulting. Each program has its own eligibility rules, co-payment ratio and eligible cost items, so always check the requirements in each call for applications.

  • Choose markets and products: Analyze procurement demand and competing products in each country
  • Prepare reference-country approvals and GMP documents: Close gaps in stability data, translations and technical files
  • Secure a local partner and file: Sign a contract that covers approval ownership, then submit the application
  • Tender and distribute: Register as a supplier, set pricing strategy and carry out the supply plan
  • Approvals in Latin America can take years, so starting early pays off. KITIM supports the full process, from building an overseas regulatory strategy to preparing applications for KHIDI and export support programs. If you are considering Brazil or Mexico, contact KITIM for an initial assessment of each product's entry potential and the support programs you can use.

    Bio-Health ExportsLatin America Market EntryANVISACOFEPRISOverseas Drug RegistrationMedical Device ExportsMOTIR

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.